We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-9.57%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$121M
AUM Growth
-$2.42M
Cap. Flow
+$13.3M
Cap. Flow %
10.95%
Top 10 Hldgs %
67.92%
Holding
31
New
5
Increased
12
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$3.46M
2
CERN
Cerner Corp
CERN
+$3.45M
3
EVH icon
Evolent Health
EVH
+$3.35M
4
FMI
Foundation Medicine, Inc.
FMI
+$2.82M
5
AMRS
Amyris Inc.
AMRS
+$2.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$3.97M
2
EXAS
Exact Sciences
EXAS
+$2.88M
3
GHDX
Genomic Health, Inc.
GHDX
+$2.6M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.2M
5
IBB icon
iShares Biotechnology ETF
IBB
+$1.45M

Sector Composition

Rank Sector Weight
1 Healthcare 81.46%
2 Materials 2.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
1
DELISTED
Sage Therapeutics
SAGE
$13.3M 10.94%
259,500
-7,000
-3% -$330K
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
$11.6M 9.55%
360,000
+69,000
+24% +$1.77M
AGIO icon
3
Agios Pharmaceuticals
AGIO
$1.84B
$10M 8.29%
240,500
-41,943
-15% -$2.2M
FMI
4
DELISTED
Foundation Medicine, Inc.
FMI
$9.66M 7.98%
546,000
+131,000
+32% +$2.82M
EVH icon
5
Evolent Health
EVH
$359M
$8.21M 6.78%
555,000
+170,000
+44% +$3.35M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$6.86M 5.66%
244,500
-42,500
-15% -$1.28M
ONCE
7
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$6.41M 5.3%
128,500
+35,000
+37% +$1.87M
GNMK
8
DELISTED
GenMark Diagnostics, Inc
GNMK
$6.24M 5.16%
510,000
-115,000
-18% -$1.37M
BLUE
9
DELISTED
bluebird bio
BLUE
$5.09M 4.2%
6,369
+1,737
+38% +$1.38M
VYGR icon
10
Voyager Therapeutics
VYGR
$179M
$4.91M 4.05%
385,000
+108,500
+39% +$1.39M
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.39M 3.63%
304,000
+64,000
+27% +$1.12M
KITE
12
DELISTED
Kite Pharma, Inc.
KITE
$4.21M 3.48%
94,000
+4,000
+4% +$196K
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$3.43M 2.83%
265,000
+105,000
+66% +$1.62M
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$3.33M 2.75%
275,000
-20,000
-7% -$209K
ILMN icon
15
Illumina
ILMN
$30.2B
$3.2M 2.64%
+25,700
New +$3.46M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.2B
$3.18M 2.63%
85,000
+46,000
+118% +$1.93M
CERN
17
DELISTED
Cerner Corp
CERN
$3.08M 2.54%
+65,000
New +$3.45M
MDRX
18
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.86M 2.36%
280,000
+80,000
+40% +$913K
AMRS
19
DELISTED
Amyris Inc.
AMRS
$2.5M 2.06%
+228,333
New +$2.8M
SYRS
20
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.21M 1.83%
18,214
+13,214
+264% +$1.85M
GNMX
21
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.94M 1.6%
375,000
– –
CTMX icon
22
CytomX Therapeutics
CTMX
$686M
$1.4M 1.16%
127,500
– –
XLRN
23
DELISTED
Acceleron Pharma
XLRN
$1.15M 0.95%
+45,000
New +$1.43M
EDIT icon
24
Editas Medicine
EDIT
$399M
$1.05M 0.87%
65,000
-20,470
-24% -$311K
GILD icon
25
Gilead Sciences
GILD
$161B
$895K 0.74%
+12,500
New +$929K
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Casdin Capital held 31 positions worth $121M, down 2% from $123M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Casdin Capital deployed $13.3M of net new capital in Q4 2016, opening 5 new positions and adding to 12 existing holdings. Its largest new stake was Illumina: 25,700 shares worth $3.2M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $2.2M trimmed.

  • Casdin Capital's largest Q4 2016 buy was Illumina: 25,700 shares worth $3.2M.
  • Casdin Capital added most to Evolent Health in Q4 2016, an estimated $3.35M increase.
  • Casdin Capital's biggest Q4 2016 reduction was Agios Pharmaceuticals, cutting an estimated $2.2M.
  • Casdin Capital fully exited Clovis Oncology, Inc. in Q4 2016, selling an estimated $3.97M.
  • Casdin Capital's ten largest holdings make up 68% of its $121M portfolio in Q4 2016.
  • Casdin Capital opened 5 new positions and closed 6 in Q4 2016.
  • Casdin Capital's portfolio value fell 2% quarter-over-quarter to $121M.

Based on Casdin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.